Clinical trials: Benign Prostatic Hypertrophy
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
BPH, Enlarged Prostate (BPH)
Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia
Purpose: The purpose of this study is to determine if prostatic artery embolization (PAE) is as effective as medication (non-inferiority) in reducing urinary symptoms due to benign prostatic hyperplasia (BPH) and to determine if…
- Conditions
- BPH, Enlarged Prostate (BPH), Prostatic Hyperplasia
- Trial name
- NCT04398966
- Testing
- Prostatic Artery Embolization (HydroPearl® compressible microspheres)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of North Carolina, Chapel Hill
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
This randomized, double-blind, placebo-controlled, six-month parallel-group study assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH) , followed by a 12-month…
- Trial name
- NCT00527605
- Testing
- Dutasteride 0.5mg capsule
- Where
- 12 sites in China
- Volunteers
- 253 people
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Benign Prostatic Hyperplasia
A Study in Men With Benign Prostatic Hyperplasia
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT01097707
- Testing
- LY500307
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Bipolar Plasmakinetic TURP Vs Monopolar TURP in the Treatment of Lower Urinary Tract Symptoms
Randomized controlled trial with one-year follow-up comparing intra, peri and postoperative outcomes for plasmakinetic transurethral resection of prostate (PK-TURP) and monopolar transurethral resection of prostate (M-TURP) in…
- Conditions
- Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Transurethral Resection of Prostate
- Trial name
- NCT03936244
- Testing
- Transurethral Resection of the Prostate (TURP)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Hospital Universitario de Fuenlabrada
Treatment of Benign Prostatic Hyperplasia
Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH
Twenty (20) subjects presenting with a hyperplasia enlarged prostate and candidates for surgery will undergo a single treatment for ablation of the prostate using the study device.
- Trial name
- NCT02683980
- Testing
- Lumenis Pulse P120H and Xpeeda side firing fiber
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation